Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Cordblood 2019

About Conference


Conference series LLC Ltd welcomes you to attend International Conference on Cord Blood Banking during April 22-23, 2019 at Vancouver, British Columbia, Canada. We cordially invite all the participants interested in sharing their knowledge and research in the area of study of banking of umbilical cord blood.

Umbilical cord blood is blood that is present in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected as it contains stem cells that are used to treat hematopoietic and genetic disorders. After a baby is born the umbilical cord is cut and some blood remains in the blood vessels of the placenta and the part of the umbilical cord that remains attached to it. After birth, the baby has no use with this extra blood. This blood is called placental blood or umbilical cord blood: "cord blood" for short. Cord blood is used the same way that hematopoietic stem cell transplantation is used to reconstitute bone marrow following radiation treatment for various blood cancers, and for various forms of anemia. Its efficacy is similar as well. Cord blood contains all the normal elements of blood - red blood cells, white blood cells, platelets and plasma. But it is also rich in hematopoietic (blood-forming) stem cells, similar to those found in bone marrow. This is why cord blood can be used for transplantation as an alternative to bone marrow. Cord blood is being used increasingly on an experimental basis as a source of stem cells, as an alternative to bone marrow. Most cord blood transplants have been performed in patients with blood and immune system diseases. Cord Blood transplants have also been performed for patients with genetic or metabolic diseases.  More than 80 different diseases have been treated to date with unrelated cord blood transplants.

Why to attend?

Conference Series Ltd organizes 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publish 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Cord blood 2019 is a 2-day event that will feature the world’s leading Cord Blood researchers, specializing in Cord Blood Banking, Clinical trials of cord blood, and Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. The Conference is an open forum for professionals to participate in meaningful and thought-provoking discussions, and network with top-industry experts. For students interested in possible STEM careers, this conference will provide a unique opportunity to learn directly from those in the cord blood industry and discover new opportunities that are emerging thanks to exciting research and current uses for cord blood stem cells. For health professionals, you will have the opportunity to meet with leading scientists in this field and understand how your practice could immediately have impact or benefit from cord blood collections. As a medical practitioner, you can also earn CME credits at this conference.

Sessions/Tracks

Track 1: Cord Blood and Cord Tissue Banking

Cord blood contains haematopoietic cells, employed in associate degree rising field of medication known as regenerative medical care. Diseases like encephalopathy, hearing impairment and polygenic disorder is also treated with wire blood. Whereas gathering bone marrow cells is painful and long, wire blood are often transplanted instantly and causes no hurt to the mother or baby.

Children from a mixed ethnic background can have a more durable time finding a bone marrow donor; therefore banking wire blood is very valuable for these patients.

  • Engraftment
  • Collection and storage
  • Successful transplants
  • Cell Engineering
  • Bioprocessing
  • Manufacturing
  • Automated Cord Blood Processing
  • Manual Cord Blood Processing

Track 2: Cord Blood Stem Cells

The scientific name for the stem cells collected from cord blood is Hematopoietic Progenitor Cells (HPC).  These cells are very valuable because they can reproduce and transform into other kinds of human cells.  This allows the body to grow new replacement cells which were also needed to treat diseases.   Most families are choosing to preserve a sample of their newborn’s cord blood in a private blood bank.  This acts as an insurance policy in case the blood is needed to treat diseases later in life. 

  • Uses
  • Treatments
  • Clinical Trails
  • Applications

Track 3: Cord Blood in Disease Treatment

Cord blood has been used for 20 years to treat more than 80 serious diseases.34 Successful treatments have opened the way for future research and today, FDA-regulated clinical trials are exploring the use of a child’s own stem cells for conditions that currently have no cure. Several of these advanced trials only use cord blood stem cells processed by Cord Blood Registry as a way of ensuring consistent quality. That means, saving with Cord Blood Registry gives families access to number of benefits and treatments. Cord blood stem cells are present being utilized as potential treatment for:

  • Cancer
  • Blood Disorders
  • Metabolic Disorders
  • Malignant and nonmalignant diseases
  • Immune Disorders
  • Neurological Disorders
  • Autoimmune Disorders
  • Heart Disorders
  • Inherited Disorders
  • Other Diseases

Track 4: Umbilical Cord Blood and Tissue-Based Therapies

Umbilical cord blood despite collected in very small volume, it contains millions of a specific type of the adult stem cell that can go on to form the blood and immune system. Because cord blood and cord tissue are each rich in a different type of stem cell, it makes sense that they would serve as treatments for different diseases or conditions. Both the hematopoietic stem cells in the cord blood and the mesenchymal stem cells in the cord tissue can be used to help heal, regenerate, or otherwise treat a variety of conditions, but the conditions and diseases that they treat don’t often overlap. The potential future use of mesenchymal stem cells, like those in cord tissue, is still being reviewed in clinical trials, but the outcomes thus far have been very promising. They are being used to treat heart and kidney disease, Amyotrophic Lateral Sclerosis (ALS), autoimmune disease, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, wound healing and even sports injuries. Cord blood is a proven treatment for more than 80 diseases, and there are a number of exciting clinical trials underway for its use in other treatments. Cord tissue has an exciting future and shows great potential for the treatment of conditions which were once untreatable.

  • Inherited metabolic disease
  • Neonatal hypoxic-ischemic encephalopathy
  • Cerebral palsy
  • Juvenile diabetes mellitus
  • Cord blood transplantation
  • Adoptive cell therapy

Track 5: Banking Cord Blood

Globally three types of cord blood banks: public, private and hybrid are available. Private Banks captured the largest revenue share owing to the high cost associated with collection and storage of cord blood unit charged to parents. Moreover, the marketing activities practiced by the private players are resulting in the increased customer base of private players compared to public banks. Considering all the above mentioned factors together, private banking service segment was leading the global market.

  • Management & Administration
  • Market for Cord Blood
  • Sustainability
  • Motivating Cord Blood Donation
  • Patient groups and clinical trials
  • Cord Blood Insurance
  • Using AI in hospitals
  • Cord blood bank models
  • Banking Processes

Track 6: Ethical and Legal Aspects of Cord Blood Banking

The collection of tissue from one individual for therapeutic use in another individual involves not only technical and medical issues, but also ethical and legal issues. Donors of cord blood are not merely depositing the leftover by-products of the birth process with interested researchers and physicians; rather, they are making a choice to do something that may potentially benefit either unknown beneficiaries or members of their own families. Pregnant women receive a great deal of information sometimes conflicting about the donation process and the consequences of different types of banking. It is important to disclose a lot of information to the potential donor, including who has access to the cord blood once it is donated, where it is stored, how it is stored, and how the donor’s privacy is protected.

  • Informed consent of donors
  • Disclosure of information regarding screening and other risks
  • Maintenance of donor records/patient privacy

Track 7: The Banking Process

For most parents, banking their baby’s umbilical cord blood and cord tissue is a new experience. At first glance, the process may seem difficult; however, it is actually very simple for the parents. Most of the mothers are worried about how the delivery will go and don’t want to also be worried about the details of collecting, processing and cryopreserving their baby’s cord blood. Generally, the healthcare provider and the cord blood bank do most of the work.

The banking process can be broken down into the following five steps:

  • Enrollment
  • Collection
  • Transportation
  • Testing and Processing
  • Preservation

Track 8: Stem Cell Banking

An amniotic stem cell bank is a facility that stores stem cells derived from amniotic fluid for future use. Stem cell samples in private banks are stored specifically for use by the individual person from whom such cells have been collected and the banking costs are paid by such person.

  • Amniotic Stem Cell Bank
  • Umbilical Cord Blood Banks
  • Hematopoietic Stem Cell And Potential Non-Hematopoietic And Stem Cells

Track 9: Tissue Regeneration

Many of us might have observed that the tail of a lizard, if cut, can grow efficiently all over again. This is an example of tissue regeneration. Like lizards, in many other animals including human’s tissue regrowth can be observed. By definition it means regrowth of damaged or affected tissue from rest of the part. The initial step is rearrangement of pre-existing tissue followed by de-differentiation and trans-differentiation of the cells. This involves cells called stem cells which have the potential to regenerate themselves. There are intrinsic signals that activate stem cells to undergo regeneration when needed. There are amazing instances of tissue regeneration, for example heart regeneration in zebra fish. In humans, liver cells can regenerate themselves. But there are many cells and tissue that lack this ability. To help humans fight tissue damages in a better way tissue regeneration needs immediate attention. Researchers across the globe should come together to unleash the mystery of the signals and genetics that trigger regeneration in some tissues.

  • Animal models of tissue regeneration
  • Molecular fundamentals of regeneration
  • Intrinsic Tissue regeneration
  • Guided Tissue Regeneration
  • Human tissue regeneration: Challenges in in-vivo and in-vitro regeneration
  • In silico Tissue engineering

Track 10: Scaffolds and Matrix for Tissue regeneration

In native state, majority of the cells (except the red blood cells) in our body are anchorage dependent and remain attached to a rigid support called extracellular matrix (ECM). It plays a key role in providing structural support to the cells and adds to the mechanical properties of tissues. It also helps the cells respond to the signals of micro-environment. Due to highly dynamic properties of ECM, it cannot be mimicked. But, scientists have developed biomaterials and biopolymers that can act as ECM and serve the similar functions in engineered tissues. The biomaterials should have some features like bioactivity, porosity, bio-compatibility etc. There are four scaffolding approaches as of now: 1) Pre-made porous scaffolds for cell seeding 2) Decellularized extracellular matrix for cell seeding 3) Confluent cells with secreted extracellular matrix 4) Confluent cells with secreted extracellular matrix. Preparation of scaffolds is a challenging task. Various approaches are Nano-fiber self-assembly, Solvent casting and particulate leachingGas foaming, Laser-assisted bio printing etc.

  • Cell seeding
  • Hydrogels
  • Cell encapsulation and microencapsulation
  • Biopolymers
  • Biomaterials.
  • Cell sheets

Track 11: Stem Cells: Culture, Differentiation and Transplantation

Stem Cells are undifferentiated cells that have the potency to regenerate and differentiate into cells of specific lineage. They are classified as oligo potent, pluripotent, totipotent cells based on the different types of cells formed after differentiation. The broader classification includes embryonic stem cells and adult stem cellsMesenchymal stem cell (MSC) is a variant of adult stem cell that gives rise to osteoblast, adipocytes and chondrocytes. MSC transplantation for tissue engineering has grabbed attention due to its immunosuppressive features. It is now in use to regenerate tissues of kidney, liver, heart; bone etc. Stem cell culture forms the base for the tissue engineering approach. A minor change in the culture environment may lead to altered potency of the cells. So special reagents and media are required. Moreover, 3D culture techniques and CRISPR genome editing technology are also in market.

  • Cancer Stem Cells
  • Mesenchymal Stem Cells
  • Stem Cell Therapy
  • Induced Pluripotent Stem cells (IPSC)

Track 12: Stem Cell and Regenerative Medicine

Stem Cells are the cells originate in all multi-cellular organisms. They are undifferentiated biological cells that can differentiate into specialized cells and can divide to produce more stem cells. Stem Cells have a capacity for self-renewal and capability of proliferation and differentiation to various cell lineages. In stem Cell therapy, or Regenerative Medicine, stem cells are used to repair, replace, or renew damaged cells including adult and embryonic stem cells

  • Sources Of Stem Cells
  • Hard Tissue Repairs and Stem Cells
  • Orthopedic Repairs and Stem Cells
  • Medical Devices and Artificial Organs
  • Advancements In Biomedical and Tissue Engineering Techniques
  • Organ Transplantation and Its New Techniques
  • Recent Innovations In Regenerative And Tissue Engineering

Track 13: Tissue Engineering

Tissue Engineering is a scientific field and also defined as understanding the principles of tissue and its growth by functional replacement of defective tissue for clinical use. Tissue engineering deals about the study of combination of cells, engineering materials methods, physicochemical and biochemical factors to replace or improve biological tissues. Tissue Engineering involves the use of Scaffolds to form functional tissues and organs, which can be implanted back into the donor host with the use of many engineering and materials methods along with some physicochemical factors. It is related to more than one branch which applies engineering knowledge and life science concepts towards the development of biological substitutes which can improve or restore physiological characteristics of organ.

  • Tissue Biomarkers
  • Mechanobiology
  • In-Site Regeneration
  • Tissue Graft Tolerance
  • Bone Materials

Market Analysis

The global cord blood banking services market is expected to reach over USD 82.3 billion by 2025, growing at an estimated CAGR of around 11.9% from 2017 to 2025. Key drivers of the market include increasing application of stem cell therapies in disease treatment, and rising prevalence of life threatening genetic disorders.

Moreover, increasing spending capacity is fueling the demand for advanced healthcare facilities including disease prevention and treatment. As a result, parents are increasingly demanding CBB services to ensure safety of their child’s future. Furthermore, private players are practicing marketing activities which are creating awareness about the availability of the CBB services and their benefits.

In European countries the price of cord tissue banking is usually half the price of cord blood banking, whereas in Asia & Oceania the prices of these two services are comparable.

Target audience:

  • Scientists
  • Researchers
  • Leading world Doctors
  • Health Professionals
  • Professors
  • Medical professionals
  • Vice Presidents/Directors and Students from universities
  • Companies, institutions and hospitals sharing their novel researches in the arena of Cord Blood Banking,  Tissue Engineering, Stem Cell and Regenerative Medicine
  • Associations
  • Societies
  • NGOs
  • Media representatives

We hope to see you at Cord Blood 2019!!

To Collaborate Scientific Professionals around the World

Conference Date April 22-23, 2019

For Sponsors & Exhibitors

sponsors@conferenceseries.com

Speaker Opportunity

Supported By

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by